Introduction
Asthma and chronic obstructive pulmonary disease (COPD) have relevant and increasing epidemiological and economic impact worldwide, [1] [2] [3] [4] with costs increasing with the worsening of the pathologies. 5, 6 As a relevant proportion of patients affected by asthma and COPD are treated with inhaled drugs, 7 an appropriate inhaler technique is necessary to obtain and maintain an effective management of these pathologies. As stated by the Guide For Asthma Management and Prevention (updated in 2015), 8 up to 80% of asthma patients do not use their inhaler adequately, and this could lead to poorer symptom control and to a higher level of exacerbations. The importance of the choice of inhaler in the treatment of COPD patients is also underlined by the 2015 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines that point out the importance of effective drug delivery and training in inhaler techniques. 9 The importance of inhaler devices for the effectiveness of inhaled drugs in the treatment of asthma and COPD is also recognized and underlined by the European Medicines Agency (EMA), which only considers approving the generic version of inhaler products if in vitro studies lead to a full therapeutic interchangeability; otherwise, lung deposition test and eventually, pharmacodynamics or even clinical studies might be required. EMA clearly stated that orally inhaled products have to be considered not as "generics" but as "hybrids". 10 A recent Italian consensus document of the Italian Society of Allergy, Asthma and Clinical Immunology and the Italian Society of Respiratory Medicine recommend that patients who are familiar and stabilized with one inhaler should not be switched to a different one without their involvement and proper training. Inappropriate inhaler use and a low adherence to inhaled treatments could lead to poorer asthma and COPD control, and switching devices without suitable training could worsen these problems.
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Because different inhalation devices require very different techniques of use, the switch of device without training in COPD and asthma patients may be associated with a poor inhalation technique with critical errors and, consequently, in a reduction of adherence and worsening in disease control. An Italian study 12 investigated the prevalence of inhalation errors and related health care resource consumption in a large population of patients with COPD and asthma.
The aim of this analysis was to estimate the possible economic impact on the Italian National Health Service (INHS) due to errors in inhalation in patients switching device without adequate training.
Materials and methods
An Italian observational, multicenter, cross-sectional study (The GENEBI Project [AIPO, Gruppo Educazionale for NEBulizers and Inhalers]) performed in 2008 conducted by Melani et al 12 investigated the prevalence of inhaler misuse and health care resource consumption in a large population of adult patients experienced in the use of inhalers which referred to chest clinics throughout Italy. A total of 1,664 patients (adolescents and adult outpatients) being treated at 24 chest clinics around Italy were enrolled, most of whom were affected by asthma (42%, mean age 51 years) and COPD (52%, mean age 70 years). All patients attended the clinics and used inhalers regularly. Mean forced expiratory volume in 1 second was 60±20 in COPD patients and 80±23 in asthma patients. Regarding inhaler education in the selected population, one-third of patients had no education, another one-third received verbal instructions, and the latter one-third received practical demonstration of inhaler use. A detailed checklist of the inhalation technique errors is reported in the paper of Melani et al. 12 The results of this study highlight higher health care resource consumption in patients experiencing critical inhaler errors vs patients without critical errors. Particularly, significantly higher rates of hospitalizations (P=0.001), emergency room (ER) visits (P,0.001), and pharmacological treatments (steroids and antimicrobials, P,0.001) were observed for both pathologies ( Table 1 ). The reported differences in resource consumption remain significant even after considering asthma and COPD separately.
For the aim of the present analysis, these differences in resource consumption were monetized from the INHS perspective by multiplying the differences in average resource consumption for their unitary cost in charge to INHS. National diagnosis related groups (DRGs) tariffs were considered for hospitalizations 13 and ER visits, 14 and the public price for drug consumption (average prices of the most widely used drugs were used to estimate the cost per course of treatment). Unitary costs considered for the base case analysis are shown in Table 2 .
In order to test the results, a sensitivity analysis was performed considering Italian real-world data for COPD and asthma hospitalizations; particularly, for COPD, a cost of €3,985/hospitalization 5 was considered while, for asthma, a cost of €2,640.75/hospitalization (adapted from Dal Negro et al 15 ) was considered. As highlighted by the unitary costs of hospitalizations derived from real-world evidences, particularly for some pathologies (ie, COPD), hospitalization-related costs could be higher than the standard DRGs tariffs and could represent valid data to perform a scenario analysis. This study was an economic evaluation based on another study (Melani et al 12 ), therefore ethical approval and patients consent were not requested.
Results
Comparing a population of 100 COPD patients with at least a critical error in inhalation with 100 COPD patients without errors in inhalation, the first population was associated with an excess of 11.5 hospitalizations, 13 ER visits, 19.5 antimicrobial courses, and 47 corticosteroids courses. In the same way, when 100 asthma patients with at least a critical error in inhalation, were compared with 100 asthma patients without errors in inhalation, the first population was associated with an excess of 19 hospitalizations, 26.5 ER visits, 4.5 antimicrobial courses, and 21.5 corticosteroids courses. These differences in resource consumption were associated with a yearly incremental health care cost for 100 patients, due to inhalation errors, of €23,444 in COPD patients and €44,104 in asthma patients (Table 3) .
The most important health care cost differences between patients with and without critical inhaler errors are related to hospitalizations (accounting for about 78% of the total difference in both pathologies) and ER visits (accounting for about 20% of the total difference).
If the Italian real-world cost data for hospitalizations was considered (already reported), as sensitivity analysis, the incremental cost per 100 patients due to critical inhaler errors increased to €50,871 in COPD patients and to €59,471 in asthma patients, with hospitalizations and ER visits being the most significant cost drivers, accounting for almost the total expenditure difference.
Discussion
Inhaled therapies have always been central to the treatment of asthma and COPD, and the Global Initiative for Asthma guidelines consider the ability to deliver drugs directly to airways a major advantage of inhaled treatment. 8 Inhaler errors represent a critical issue in the management of COPD and asthma patients, as they are associated with worsening in disease control, increased rate of exacerbation in COPD patients, increased health care resource consumption, and consequently, increased health care expenditure.
The importance of correct inhalation technique and the correlation between the switch of inhaler therapy, and a worsening in the pathology control, a deterioration in the quality of life of patients, and an increase in resource consumption are widely recognized. [16] [17] [18] [19] [20] [21] With patents expiring for some of the most widely used inhaled drugs, several analogs of branded inhaled corticosteroids/long-acting β-adrenoceptor agonists fixed-dose combinations are entering the market with different inhaler devices.
To improve inhaler techniques and reduce critical inhalation errors, adequate training is essential when a patient is switched from one device to another. 18, [22] [23] [24] [25] [26] [27] [28] [29] A very recent study 30 highlighted the possible issues related to nonconsented inhaler switches without adequate training in COPD patients and the relevance of the economic implications of inappropriate switching without performing a specific economic analysis.
The present analysis, which applies Italian health care costs to differences in resource consumption between patients with and without critical errors in the use of inhaler devices reported in a real-world study, highlights the relevance of health care cost increases related to errors in inhalation techniques. Costs ranged from approximately €200 to €600/ patient/year (which represented, even without taking into consideration the clinical consequences, a relevant part of the yearly cost of the most widely used inhaled drugs).
While it may appear to be a benign decision, changing or switching inhaler device can have a large effect on disease control. Because different devices require very different techniques for use, switching inhaler device (in particular, nonconsensual switches) may be associated with a poor inhalation technique unless patients are carefully counseled.
It is therefore crucial to consider all relevant costs, including those related to training sessions, additional consultations, repeated prescriptions, and management of acute events: these costs may contribute to reduce the potential benefit coming from switching inhalers. These economic considerations, associated with previously reported clinical issues related to the untrained switch of inhaler devices, emphasize the importance of carefully considering switching, with particular regard to those patients who are familiar and stabilized on one type of inhaler.
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